

## SPECIAL SESSION



---

### Speakers:

Mr. Gary Wright, Chief of Contract Operations;  
Mr. Al Burket, Director, Joint Omnibus Management Office, and, Mr. Tim Belski, Joint Product Director, Advanced Development and Manufacturing Capabilities  
Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD)

### Doing Business with the JPEO

The Joint Program Executive Office for Chemical and Biological Defense exists to manage our nation's investments in chemical, biological, radiological, and nuclear (CBRN) defense equipment. JPEO will present a contracting landscape overview at the 2017 Chemical and Biological Defense Science & Technology (CBD S&T) Conference, describing opportunities to work with the JPEO. We will address the roles small businesses can play in driving innovation for improving the next generation's capability sets, its award of a Countering Weapons of Mass Destruction (CWMD) Other Transaction Agreement (OTA) to the National Chemical and Biological Defense Consortium, and its use of Omnibus Vehicles for the majority of future contracting needs. The CWMD OTA will allow the JPEO-CBD to rapidly develop new technologies as well as improve upon existing capabilities. In addition, the Joint Enterprise-Research Development Acquisition Production/Procurement (JE-RDAP) contract's task/delivery orders provide for CBRNE Defense Systems, Capabilities, Equipment, Supplies and Material; Medical Devices, Radiological/Nuclear Defense Systems, and CBRNE Information Systems. In April 2016, the Department of Defense awarded an OTA to the Medical CBRN Defense Consortium (MCDC), managed by ATI Inc. The OTA-Consortium business model is a partnership between the Government and a consortium of technology developers/providers in a specific domain, where The Government partner can be a single sponsor or multiple sponsors coordinated through a lead agency, and the "Consortium" partner is a group of for-profit, not-for-profit and/or non-profit companies, universities and other academic research organizations having competence in the technical domain of interest. The parties are connected through a binding "contract-like" instrument called an "Other Transaction" that operates outside the normal Federal Acquisition Regulations (FAR). The DoD is utilizing this unique arrangement to develop prototypes in the prevention (vaccines and pretreatments), diagnostic, and treatment objective areas.

Finally, to keep the industrial base well-informed of future business opportunities, the direction of the Chemical and Biological Defense program and any future requirements of the Department of Defense will be addressed.